金属配位多锌三碘甲状腺原氨酸在甲减大鼠中提供稳定的循环T3水平
该研究合成金属配位形式的三碘甲状腺原氨酸(PZL),装入胶囊递送至十二指肠实现缓释。在甲减雄性Wistar大鼠中比较PZL与等摩尔LT3的药代动力学和生物学效应,发现PZL降低并延迟血清T3峰值,延长平台时间,同时恢复T3依赖的生物学效应。
要点
- PZL胶囊使甲减大鼠血清T3峰值降低约30%并延迟至9小时出现。
- PZL使血清T3至少半峰值的平台时间从LT3的4.9小时延长至7.7小时。
- PZL与LT3均恢复生长、降低胆固醇并诱导T3依赖标志物。
核心结论
- 口服PZL胶囊可恢复T3依赖的生物学效应,同时降低并延迟给药后血清T3峰值,提供比LT3胶囊更长时间相对稳定的血清T3水平。
研究设计与样本
- 研究合成金属配位LT3(Zn[T3][H2O])n即PZL并装入胶囊递送至十二指肠缓释。
- 雄性Wistar大鼠经低碘饮食和0.05%甲巯咪唑水喂养五至六周造成甲减。
- 大鼠给予含24 μg/kg PZL或等摩尔LT3的胶囊,前16小时内多次尾静脉采血测T3和TSH,部分动物每日给药8天并每日采血。
主要发现
- LT3组给药后3.5小时出现约五倍基线的血清T3峰值,随后快速下降,16小时几乎回到基线。
- PZL组血清T3峰值降低约30%,出现于9小时,平台时间从LT3的4.9小时延长至7.7小时。
- 两组血清TSH均下降,但PZL组下降更渐进,较LT3组延迟约四小时。
- 长期LT3或PZL治疗均恢复生长、降低血清胆固醇并刺激肝脏Dio1 mRNA及中枢神经系统其他T3依赖标志物表达。
临床怎么用
- PZL可能为需要长期LT3治疗的患者提供更平稳的血清T3水平,减少给药后峰值。
- PZL的TSH下降更渐进且延迟,临床监测需考虑其时相差异。
局限性
- 研究为甲减大鼠模型,样本量未报告,结果外推至人类需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liothyronine (LT3) has limited short-term clinical applications, all of which aim at suppressing thyrotropin (TSH) secretion. A more controversial application is chronic administration along with levothyroxine in the treatment of hypothyroidism. Long-term treatment with LT3 is complicated by its unique pharmacokinetics that result in a substantial triiodothyronine (T3) peak in the blood three to four hours after oral dosing. This is a significant problem, given that T3 levels in the blood are normally stable, varying by <10% throughout the day. METHODS: A metal coordinated form of LT3 (Zn[T3][H2O])n, known as poly-zinc-liothyronine (PZL), was synthesized and loaded into coated gelatin capsules for delivery to the duodenum where sustained release of T3 from PZL occurs. Male Wistar rats were made hypothyroid by feeding on a low iodine diet and water containing 0.05% methimazole for five to six weeks. Rats were given a capsule containing 24 μg/kg PZL or equimolar amounts of LT3. Blood samples were obtained multiple times from the tail vein during the first 16 hours, and processed for T3 and TSH serum levels. Some animals were treated daily for eight days, and blood samples were collected daily. RESULTS: Rats given LT3 exhibited the expected serum T3 peak (about fivefold baseline) at 3.5 hours, followed by a rapid decline, with serum levels almost returning to baseline values by 16 hours. In contrast, serum T3 in PZL-treated rats exhibited about a 30% lower T3 peak at nine hours. Furthermore, the plateau time, that is, the time-span during which the serum T3 concentration is at least half of T3 peak, increased from 4.9 to 7.7 hours in LT3- versus PZL-treated rats, respectively. Serum TSH dropped in both groups, but PZL-treated rats exhibited a more gradual decrease, which was delayed by about four hours compared to LT3-treated rats. Chronic treatment with either LT3 or PZL restored growth, lowered serum cholesterol, and stimulated hepatic expression of the Dio1 mRNA and other T3-dependent markers in the central nervous system. CONCLUSION: Capsules of PZL given orally restore T3-dependent biological effects while exhibiting a reduced and delayed serum T3 peak after dosing, thus providing a longer period of relatively stable serum T3 levels compared to capsules of LT3.
引用
- Da Conceição RR, Fernandes GW, Fonseca TL, et al. Metal Coordinated Poly-Zinc-Liothyronine Provides Stable Circulating Triiodothyronine Levels in Hypothyroid Rats. Thyroid. 2018. PMID: 30301431. doi:10.1089/thy.2018.0205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。